Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Q2 2024 Earnings Presentation
61 slides from Takeda Pharmaceutical's earnings presentation, Oct 31, 2024
Slide 1: Committed to Growth & Shareholder Returns
TSE: 4502 Committed to Growth & Shareholder Returns FY2024 Q2 Earnings Announcement October 31st, 2024
Slide 2: Important Notice
Important Notice For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this presentation. This presentation (i
Slide 3: Agenda
Opening Remarks & Business Highlights Christophe Weber, President & CEO Financial Highlights Milano Furuta, Chief Financial Officer AGENDA Pipeline Update Andy Plump, President, R&D Q&A Question & Answer Session
Slide 4: Positive First Half of FY2024 with Momentum in Portfolio & Pipeline
Positive First Half of FY2024 with Momentum in Portfolio & Pipeline Strong Momentum of Driving Efficiencies to Progress in Late-Stage Growth & Launch Products Improve Margins Innovative Pipeline • Total H1 Revenue of JPY 2,384.0B • Core Operating Profit margin 30.2%3 • TAK-861 transformative long-te
Slide 5: Strong Momentum of Growth & Launch Products +18.7% at CER
Strong Momentum of Growth & Launch Products +18.7% at CER Balanced Portfolio Across 6 Key Business Areas PLASMA-DERIVED GI RARE DISEASES THERAPIES (PDT) ONCOLOGY VACCINES NEUROSCIENCE % of Sales: 29% % of Sales: 16% % of Sales: 22% % of Sales: 12% % of Sales: 2% % of Sales: 13% Growth at CER: +8% Gr
Slide 6: Strong Uptake of New Products Launched within Past 12 Months
Strong Uptake of New Products Launched within Past 12 Months U.S. Launch in November 2023 U.S. Launch in November 2023 congenital thrombotic metastatic colorectal cancer (mCRC) thrombocytopenic purpura (cTTP) • Exceeding expectations with significant uptake in U.S. • High prescriber interest in area
Slide 7: Return to Double-Digit Growth at CER with Acceleration Driven by ENTYVIO Pen
Return to Double-Digit Growth at CER with Acceleration Driven by Launch of ENTYVIO Pen in the U.S. +10.7% FY2024 H1 Sales Growth at CER accelerating from +6.6% in FY2023; continuing to outperform the overall IBD advanced therapy market ENTYVIO Pen launched in the U.S. Nov 2023 (UC); April 2024 (Croh
Slide 8: Agenda
Opening Remarks & Business Highlights Christophe Weber, President & CEO Financial Highlights Milano Furuta, Chief Financial Officer AGENDA Pipeline Update Andy Plump, President, R&D Question & Answer Session
Slide 9: FY2024 H1 Results Driven by Growth & Launch Products
FY2024 H1 Results Driven by Growth & Launch Products, Continued VYVANSE Demand, and Phasing of R&D Investment FY2024 H1 (APR-SEP) FINANCIAL RESULTS (SUMMARY) (BN YEN, except EPS) REPORTED CORE1 ACTUAL % ACTUAL % FY2024 H1 FY2023 H1 CHANGE FY2024 H1 FY2023 H1 CHANGE CER2 % CHANGE REVENUE 2,384.0 2,10
Slide 10: FY2024 H1 Revenue: Growth & Launch Products More Than Offset LOE Impact
FY2024 H1 Revenue: Growth & Launch Products More Than Offset LOE Impact FY2024 H1 REVENUE VS PRIOR YEAR (BN JPY) +13.4% 2,384.0 +5.0% at CER 176.5 2,101.7 Includes VYVANSE, Growth of AZILVA & ADDERALL XR +18.7% at CER FY2023 H1 Growth & Launch LOE impacted Other products FX FY2024 H1 Revenue Product
Slide 11: FY2024 H1 Core Operating Profit: Growth & Launch Products More Than Offset LOE Impact
FY2024 H1 Core Operating Profit: Growth & Launch Products More Than Offset LOE Impact and Benefit from Phasing of R&D Investment FY2024 H1 CORE OPERATING PROFIT VS PRIOR YEAR (BN JPY) +22.3% +12.9% at CER 719.9 55.3 588.8 Gross Profit Impact FY2023 H1 Growth & Launch LOE impacted products R&D and DD
Slide 12: FY2024 H1 Reported Operating Profit: Increase Mainly Due to Non-Core Items
FY2024 H1 Reported Operating Profit: Increase Mainly Due to Large Non-Core Items Booked in the Prior Fiscal Year FY2024 H1 REPORTED OPERATING PROFIT VS PRIOR YEAR (BN JPY) +194.0% 350.6 25.0 Lower legal provision & reversal of pre-launch inventory, partially offset by higher restructuring cost Reduc
Slide 13: Enterprise-wide Program to Drive Efficiencies
We Have Initiated an Enterprise-wide Program to Drive Efficiencies Organizational Agility Focus on agility and organizational simplicity, Freeing up resources to: reducing layers, broadening spans, » Advance prioritized pipeline and refining operating models » Execute new product launches » Continue
Slide 14: Efficiency Program Implementation is Progressing as Planned
Efficiency Program Implementation is Progressing as Planned • Structural changes across various corporate and regional functions JPY 61.6B Organizational • R&D pipeline prioritization & exiting research site in San Diego restructuring costs • Announced early retirement program (Future Career Program
Slide 15: Raising Full-Year FY2024 Management Guidance and Forecasts
Raising Full-Year FY2024 Management Guidance and Reported & Core Forecasts CORE CHANGE AT CER (MANAGEMENT GUIDANCE) ORIGINAL GUIDANCE REVISED GUIDANCE REVENUE Flat to slightly declining Flat to slightly increasing CORE OPERATING PROFIT Approx 10% decline Mid-single-digit % decline CORE EPS Mid-10s%
Slide 16: FY2024 Forecast Upgrade Driven by Product Momentum Including VYVANSE
FY2024 Forecast Upgrade Driven by Product Momentum Including VYVANSE FY2024 REVENUE FORECAST (OCT VS MAY) FY2024 CORE OPERATING PROFIT FORECAST (OCT VS MAY) (BN JPY) 4,480.0 1,050.0 4,350.0 1,000.0 FY2024 Original VYVANSE Other FX FY2024 Revised FY2024 Original VYVANSE Other OPEX FX Impact FY2024 Re
Slide 17: FY2024 H2 vs H1: VYVANSE Generic Erosion & Ramp-up in R&D
FY2024 H2 vs H1: Assumes Acceleration of VYVANSE Generic Erosion & Ramp-up in R&D Investment FY2024 CORE OPERATING PROFIT FORECAST (H2 ASSUMPTION VS H1 ACTUAL) (BN JPY) 719.9 Primarily due to acceleration of VYVANSE generic erosion in H2; also impact of shipment and tender timings Forecast reflects
Slide 18: Agenda
Opening Remarks & Business Highlights Christophe Weber, President & CEO Financial Highlights Milano Furuta, Chief Financial Officer AGENDA Pipeline Update Andy Plump, President, R&D Question & Answer Session
Slide 19: Major Updates to Our Late-Stage Pipeline Since FY2024 Q1
Major Updates to Our Late-Stage Pipeline Since FY2024 Q1 TAK-861 Phase 3 start for the first oral orexin 2 receptor agonist in August 2024 TAK-861 At Sleep Europe 2024, transformative long-term Phase 2b data were presented in NT1 patients to 6 months and beyond. Also presented, positive Data & impac
Slide 20: R&D Day: Focus on Late-Stage Pipeline and Market Opportunity
R&D Day: Focus on Late-Stage Pipeline and Market Opportunity When December 13 from 8:30 AM JST / December 12 from 6:30 PM EST Duration of event is expected to be approximately 5 hours Format Hybrid event: Live presentation in Tokyo with virtual webcast For registration to the webcast, please visit t
Slide 21: Q&A Session
Q&A CHRISTOPHE WEBER MILANO FURUTA ANDY PLUMP RAMONA SEQUEIRA Representative Director; Director; Director; President, President, President & CEO Chief Financial Officer Research & Development Global Portfolio Division SESSION JULIE KIM GILES PLATFORD TERESA BITETTI President, President, Plasma- Pres
Slide 22: Appendix
APPENDIX
Slide 23: FY2024 H1 Adjusted Free Cash Flow of ~JPY250B
FY2024 H1 Adjusted Free Cash Flow of ~JPY250B FY2024 H1 CASH FLOW Total liquidity of JPY 1.5T (USD 10.3B)2 including JPY 700B from undrawn committed line of credit (BN JPY) and excluding pass-through cash Adjusted Free Cash Flow1 247.5 147.3 13.8 33.1 859.0 40.8 106.9 91.6 700.4 Includes proceeds fr
Slide 24: Hybrid Debt Refinancing Completed; No More Debt Maturities in FY2024
Hybrid Debt Refinancing Completed; No More Debt Maturities Outstanding in FY2024 MATURITY LADDER AS OF 30 SEPTEMBER 2024 (AS ADJUSTED) 1 800 600 BILLION JPY HYBRID BONDS2 PAID OFF 400 HYBRID DEBT3 IN OCTOBER 2024 200 - ‖ ‖ ‖ ‖ ‖ ‖ ‖ ‖ FY 24 FY 25 FY 26 FY 27 FY 28 FY 29 FY 30 FY 31 FY 32 FY 34 FY 40
Slide 25: ENTYVIO Growth Acceleration Driven by U.S. Launch of ENTYVIO Pen
G A ST RO E N TE RO LO GY (G I ) ENTYVIO Growth Acceleration Driven by U.S. Launch of ENTYVIO Pen GI PORTFOLIO FY2024 H1 Revenue JPY 473.2B (+10.7% growth) FY2024 H1 REVENUE (BN JPY) • ENTYVIO growth continues to outperform the overall IBD market • In the U.S., ENTYVIO remains the #1 brand in IBD (U
Slide 26: Sustained TAKHZYRO Momentum; LIVTENCITY Market Penetration
R A R E D I SE A SE S Sustained TAKHZYRO Momentum with Double-Digit Growth LIVTENCITY Strong Market Penetration in U.S. & Rapid Geographical Expansion RARE DISEASES PORTFOLIO FY2024 H1 Revenue JPY 111.0B (+16.7% growth) FY2024 H1 REVENUE • 6 years in the market, TAKHZYRO continues to be the #1 presc
Slide 27: PDT Portfolio Continues to Deliver Outstanding Growth
P LA S MA - D E RI V E D T H E R A P I E S PDT Portfolio Continues to Deliver Outstanding Growth Fueled By Sales of Immunoglobulin Products PDT PORTFOLIO Immunoglobulin Albumin FY2024 H1 REVENUE FY24 H1 Revenue JPY 391.0B (+15.9% growth) FY24 H1 Revenue JPY 70.3B (+11.0% growth) (BN JPY) • Strong de
Slide 28: Steady Growth Across Key Brands in Oncology Marketed Portfolio
O N C O LO G Y Steady Growth Across Key Brands in Oncology Marketed Portfolio ONCOLOGY PORTFOLIO FY2024 H1 REVENUE FY2024 H1 Revenue JPY 23.1B (Newly Launched) (BN JPY) • Launch has exceeded expectations, with strong uptake in the U.S. and early positive start in Germany; full-year revenue forecast
Slide 29: QDENGA Demand Exceeding Expectations
VACCINES QDENGA Demand Exceeding Expectations; Driving Awareness and Access VACCINES PORTFOLIO FY2024 H1 Revenue JPY 19.9B (+863% growth) FY2024 H1 REVENUE (BN JPY) • Strong global demand: now available in 25 countries, including 18 European countries with travel recommendations to support use of QD
Slide 30: VYVANSE U.S. Loss of Exclusivity Impact from August 2023
N E UR O SC I E N CE VYVANSE U.S. Loss of Exclusivity Impact from August 2023 NEUROSCIENCE PORTFOLIO FY2024 H1 Revenue JPY 203.2B (-17.9% change) FY2024 H1 REVENUE (BN JPY) Vyvanse U.S. Weekly Volume (million units)2 • U.S. revenue declined -28.6% at CER in H1, impacted by Loss of Exclusivity that o
Slide 31: Late-Stage Programs have the Potential to Generate Significant Value
Developing Life Transforming Medicines for Rare and More Prevalent Diseases: Late-Stage Programs have the Potential to Generate Significant Value FY24 FY25 FY26-27 Psoriasis Psoriasis Head-to-Head vs. deucravacitinib Start Target Filling zasocitinib Psoriatic Arthritis Psoriatic Arthritis (TAK-279)
Slide 32: Pipeline Milestones for Early to Mid-Stage Programs
Impactful Pipeline Milestones for Early to Mid-Stage Programs Advance Science and Address Unmet Patient Needs FY24 FY25 COMMENTS Celiac Disease TAK-227 Phase 2b GASTROINTESTINAL AND INFLAMMATION TAK-007 Lupus Nephritis Proof-of-Mechanism in (CAR-NK Platform) Autoimmune Disease Trial stopped due to e
Slide 33: Important Near-Term LCM Expansions Represent Growth Opportunities
Important Near-Term LCM Expansions Represent Significant Growth Opportunities FY24 FY25 GASTROINTESTINAL maralixibat ENTYVIO AND INFLAMMATION Filed ALGS, PFIC (Japan) Target Filing Crohn’s/UC Peds (US, EU) ADCETRIS Filed FL HL BrECADD (EU)1 ONCOLOGY CABOMETYX Target Filing CRPC (Japan) HYQVIA Filed
Slide 34: Potential NME Approvals and Indication Expansions in FY24
Potential NME Approvals and Indication Expansions in FY24 ENTYVIO SC Crohn’s disease U.S. approval QDENGA Dengue vaccine Additional endemic countries1 ADZYNMA cTTP EU approval KEY POTENTIAL EU approval FRUZAQLA mCRC REGULATORY JP approval APPROVALS LIVTENCITY Refractory post-transplant CMV infection
Slide 35: Consolidated Development Pipeline by Phase
Consolidated Development Pipeline by Phase PHASE 3 (6 NMEs + 13 LCMs) FILED (2 NME + 10 LCMs) zasocitinib rusfertide ADZYNMA® fazirsiran ADZYNMA® Psoriasis Polycythemia Vera cTTP (CN) AATD Liver Disease cTTP (EU) GASTROINTESTINAL AND INFLAMMATION ALOFISEL® ENTYVIO® ENTYVIO® ENTYVIO® Pediatric Perian
Slide 36: Consolidated Development Pipeline by Phase
Consolidated Development Pipeline by Phase PHASE 1 (5 NMEs) PHASE 2 (11 NMEs + 1 LCM) mezagitamab zasocitinib zasocitinib TAK-101 ADZYNMA® IgAN Psoriatic Arthritis Crohn’s Disease Celiac Disease iTTP GASTROINTESTINAL AND INFLAMMATION zasocitinib TAK-227 zamaglutenase mezagitamab Ulcerative Colitis C
Slide 37: Advancing Zasocitinib (TAK-279) In Parallel Across Multiple Indications
Advancing Zasocitinib (TAK-279) In Parallel Across Multiple Indications Phase 2 Start Phase 2b Readout Phase 3 Target Filing Ph2b March 2023 Ph3 Start FY23 FY26-27 Psoriasis Head-to-Head Start FY24/25 Psoriatic Arthritis Ph2b September 2023 Ph3 Start FY24 Crohn’s Disease Ph2b March 2024 Zasocitinib
Slide 38: Continuing Evidence Generation and Indication Expansion
Continuing Evidence Generation and Indication Expansion PHASE 3 PHASE 3b / 4 PUBLISHED APPROVED ENTYVIO® IV ENTYVIO® IV (VERDICT) ENTYVIO® IV (VARSITY) ENTYVIO® IV Pediatric (Global) (Global)3,4 ENT vs. ada1 (Global) Ulcerative colitis ENTYVIO® IV (EXIGEM) ENTYVIO® SC ENT + tof (US/Can)3 (US, EU, JP
Slide 39: Glossary of Abbreviations
Glossary of Abbreviations Regional Abbreviations: EGFR epidermal growth factor receptor LCM lifecycle management POC proof of concept CN: China; EU: Europe; JP: Japan; UK: United Kingdom; U.S.: EMA European Medicines Agency LGS Lennox-Gastaut syndrome PR platelet response United States of America ES
Slide 40: Financial Appendix
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2024 H1 Reported Results with CER % Change A-4 FY2024 Q2 (Jul-Sep) Reported Results with CER
Slide 41: Definition and Explanation of Non-IFRS Measures
Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations Core Financial Measures Takeda’s Core Financial Measures, particularly Core Revenue, Core Operating Profit, Core Net Profit for the Year attributable to owners of the Company and Core EPS, exclude revenue from d
Slide 42: Free Cash Flow and Adjusted Free Cash Flow
Free Cash Flow and Adjusted Free Cash Flow Takeda defines Free Cash Flow as cash flows from operating activities less acquisition of property, plant and equipment (“PP&E”). Takeda defines Adjusted Free Cash Flow as cash flows from operating activities, subtracting payments for acquisition of PP&E, i
Slide 43: Net Debt and Adjusted Net Debt
Net Debt and Adjusted Net Debt Takeda defines Net Debt as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents, and Adjusted Net Debt first by calculating the sum of the current and non-current portions of bonds and loans as s
Slide 44: FY2024 H1 Reported Results with CER % Change
FY2024 H1 Reported Results with CER % Change vs. PY (Million USD, except EPS) FY2023 FY2024 AER CER (Billion JPY, except EPS) FY2024 H1 H1 H1 Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 2,101.7 2,384.0 282.3 13.4% 5.0% 16,642 Cost of sales (664.7) (781.3) (116.6) (17.5)% (
Slide 45: FY2024 Q2 Reported Results with CER % Change
FY2024 Q2 (Jul-Sep) Reported Results with CER % Change vs. PY (Million USD, except EPS) FY2023 Q2 FY2024 Q2 AER CER (Billion JPY, except EPS) FY2024 Q2 (Jul-Sep) (Jul-Sep) (Jul-Sep) Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 1,043.1 1,176.0 132.9 12.7% 8.0% 8,210 Cost of
Slide 46: FY2024 H1 Core Results with CER % Change
FY2024 H1 Core Results with CER % Change vs. PY (Million USD, except EPS) FY2023 FY2024 AER CER (Billion JPY, except EPS) FY2024 H1 H1 H1 Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 2,101.7 2,384.0 282.3 13.4% 5.0% 16,642 Cost of sales (664.8) (781.5) (116.6) (17.5)% (9.2)
Slide 47: FY2024 Q2 Core Results with CER % Change
FY2024 Q2 (Jul-Sep) Core Results with CER % Change vs. PY (Million USD, except EPS) FY2023 Q2 FY2024 Q2 AER CER (Billion JPY, except EPS) FY2024 Q2 (Jul-Sep) (Jul-Sep) (Jul-Sep) Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 1,043.1 1,176.0 132.9 12.7% 8.0% 8,210 Cost of sale
Slide 48: FY2024 H1 Reconciliation from Reported to Core
FY2024 H1 Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE Teva JV related intangible intangible operating income/ Others adjustment*2 assets assets expenses Revenue 2,384.0 2,384.0 Cost
Slide 49: FY2024 Q2 Reconciliation from Reported to Core
FY2024 Q2 (Jul-Sep) Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE Teva JV related intangible intangible operating income/ Others adjustment*2 assets assets expenses Revenue 1,176.0 1,
Slide 50: FY2023 H1 Reconciliation from Reported to Core
FY2023 H1 Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 2,101.7 2,101.7 Cost of sales (664.7) (0.1) (664.
Slide 51: FY2023 Q2 Reconciliation from Reported to Core
FY2023 Q2 (Jul-Sep) Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 1,043.1 1,043.1 Cost of sales (343.6) (
Slide 52: FY2024 H1 Adjusted Free Cash Flow
FY2024 H1 Adjusted Free Cash Flow (Million USD) FY2023 FY2024 FY2024 H1 (Billion JPY) vs. PY H1 H1 Convenience USD Translation Net profit 41.4 187.4 146.0 352.3 % 1,308 Depreciation, amortization and impairment loss 480.9 420.7 (60.2) 2,937 Decrease (increase) in trade working capital (200.7) (146.1
Slide 53: FY2024 H1 Adjusted Net Debt to Adjusted EBITDA
FY2024 H1 Adjusted Net Debt to Adjusted EBITDA NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS FY2024 FY2023 FY2024 (Billion JPY) H1 (Billion JPY) vs. PY H1 H1 Book value of bonds and loans on consolidated statements of Net cash from operating activities (Operatin
Slide 54: FY2023 Adjusted Net Debt to Adjusted EBITDA
FY2023 Adjusted Net Debt to Adjusted EBITDA NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (Billion JPY) FY2023 (Billion JPY) FY2022 FY2023 vs. PY Book value of bonds and loans on consolidated statements of Net cash from operating activities (Operating Cash Flow)
Slide 55: FY2024 H1 Net Profit to Adjusted EBITDA Bridge
FY2024 H1 Net Profit to Adjusted EBITDA Bridge FY2023 FY2024 (Billion JPY) vs. PY H1 H1 Net profit 41.4 187.4 146.0 352.3 % Income tax expenses (benefit) (2.4) 68.6 Depreciation and amortization 354.2 384.7 Interest expense, net 54.0 58.3 EBITDA 447.2 699.0 251.8 56.3 % Impairment losses 126.7 36.1
Slide 56: FY2024 H1 Net Profit to Adjusted EBITDA LTM Bridge
FY2024 H1 Net Profit to Adjusted EBITDA LTM Bridge FY2023 FY2023 FY2024 FY2024 (Billion JPY) Full Year H1 H1 H1 LTM*1 (Apr - Mar) (Apr - Sep) (Apr - Sep) (Oct - Sep) Net profit 144.2 41.4 187.4 290.2 Income tax expenses (benefit) (91.4) (2.4) 68.6 (20.5) Depreciation and amortization 728.0 354.2 384
Slide 57: FY2024 H1 CAPEX, Depreciation and Amortization and Impairment Losses
FY2024 H1 CAPEX, Depreciation and Amortization and Impairment Losses FY2023 FY2024 FY2024 Revised Forecast (Billion JPY) vs. PY H1 H1 (October 31, 2024) Capital expenditures*1 339.3 198.5 (140.8) (41.5)% 380.0 - 420.0 Tangible assets 83.8 106.9 23.1 27.6 % Intangible assets 255.5 91.6 (163.9) (64.2)
Slide 58: FY2024 Full Year Detailed Forecast
FY2024 Full Year Detailed Forecast Original Forecast Revised Forecast vs. Original (BN JPY) Variances (May 9, 2024) (October 31, 2024) Forecast Revenue 4,350.0 4,480.0 130.0 3.0 % Business momentum including Vyvanse and FX benefit Cost of sales (1,500.0) (1,555.0) (55.0) (3.7)% Gross Profit 2,850.0
Slide 59: FY2024 Full Year Reconciliation from Reported to Core Operating Profit Forecast
FY2024 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast REPORTED TO CORE ADJUSTMENTS Other operating (Billion JPY) REPORTED Amortization of Impairment of CORE income (expenses) intangible intangible and other assets assets adjustments Revenue 4,480.0 4,480.0
Slide 60: FY2024 Full Year FX Rates Assumptions and Currency Sensitivity
FY2024 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast Average Exchange Rates vs. JPY Impact of depreciation of yen from October 2024 to March 2025 (100 million JPY) Core FY2023 H1 FY2024 H1 FY2024 Full Year FY2024 H2 Operating Revenue Net Profit Operating Actual Actual Assumpti
Slide 61: Takeda Investor Relations
Takeda Investor Relations: takeda.ir.contact@takeda.com © 2024 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda Pharmaceutical Company — Q2 2024 Earnings Presentation on 6ix